Day: July 3, 2024

VANCOUVER, British Columbia, July 03, 2024 (GLOBE NEWSWIRE) — Blender Bites Limited (the “Company”, “Blender Bites” or “Blender”), (CSE: BITE, FWB: JL4, WKN: A3DMEJ), a multi award-winning Canadian company involved in the development and marketing of a line of premium, organic and plant-based pre-portioned frozen functional foods, is excited to announce that its Superberry Sport™ powered by Orgain and Liquid Sunshine™ 1-Step Smoothies are now on shelves in 151 locations in one of the leading operators of membership warehouse clubs (the “Wholesale Club Chain” or “Chain”) in the United States. This expansion into the Wholesale Club Chain spans 16 states, marking significant progress in Blender Bites’ growth and accessibility in the United States. In addition, Blender Bites’ new flavor Superberry Sport™...

LOUISVILLE, Ky., July 03, 2024 (GLOBE NEWSWIRE) — Texas Roadhouse, Inc. (NasdaqGS: TXRH) announced today that it will release second quarter 2024 financial results on Thursday, July 25, 2024 after the market close. A conference call will follow at 5:00 PM ET and will be webcast live from the investor relations portion of the Company’s website at www.texasroadhouse.com. Listeners may also access the call by dialing (888) 440-5667 or (646) 960-0476 for international calls and referencing the Texas Roadhouse, Inc. Second Quarter 2024 Earnings. A replay of the call will be available until August 1, 2024 by dialing (800) 770-2030 or (609) 800-9909 for international calls and using conference ID 7714420. About the Company Texas Roadhouse is a growing restaurant company operating predominantly in the casual dining segment that first...

Multiple studies confirm ART12.11’s superior advantages as a product candidate for the treatment of anxiety related disorders SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today announced several presentations about ART12.11, Artelo’s proprietary cocrystal combination drug candidate, were delivered at the 34th Annual International Cannabinoid Research Society (ICRS) Symposium held June 30 through July 5, 2024 in Salamanca, Spain. Andrew Yates, Ph.D., Chief Scientific Officer at Artelo, presented results from two studies entitled, “ART12.11, a Novel Cannabidiol: Tetramethylpyrazine Cocrystal, Demonstrates...

ASHEVILLE, N.C., July 03, 2024 (GLOBE NEWSWIRE) — HomeTrust Bancshares, Inc. (NASDAQ: HTBI) (“Company”), the holding company of HomeTrust Bank (“Bank”, “HomeTrust” or “HTB”), today announced that the Bank has been named a 2024 Best Place to Work in South Carolina by Best Companies Group. “We are very proud of this recognition in South Carolina,” said C. Hunter Westbrook, President & Chief Executive Officer. “HomeTrust has always had the goal of being a high performing regional community bank, and we believe the most important strategic initiative to achieve this goal was to create a recognized best place to work with a culture that created a sense of belonging. Happy, engaged teammates serve customers better and drive higher results.” To receive this recognition, companies across South Carolina completed a two-part survey...

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company’s ongoing human clinical trial THE WOODLANDS, TX , July 03, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the current standard of care for people with pancreatic cancer pain and how Autonomix is working to significantly advance pain management and allow for more effective intervention with fewer side effects...

WOBURN, Mass., July 03, 2024 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a global leader in AI-powered marketing technology, today announced that one of the top 10 leading electrical distributors in the United States has chosen Bridgeline’s HawkSearch to handle their sophisticated search needs across hundreds of local store websites. HawkSearch’s merchandising capabilities will increase sales across nearly one thousand local store websites by improving navigation within the distributor’s catalog of five million products. Through HawkSearch’s new Multi-Engine Management (MEM) feature, the distributor can easily make corporate changes to hundreds of local store websites. Additionally, HawkSearch enables each store to implement targeted local campaigns. The MEM feature provides scale and control for the corporate...

SHOUGUANG, China, July 03, 2024 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (Nasdaq: GURE) (“Gulf Resources”, “we,” or the “Company”), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that its wholly owned subsidiary, Shouguang Hengde Salt Industry Co. Ltd (“SHSI”), entered into a series of agreements to acquire crude salt fields for an aggregate price of RMB280,762,000 (approximately US$38,619,257 based on the current exchange rate on July 3, 2024). The purchase includes 5 parcels of crude salt fields with a total size of 5,141,000 square meters (approximately 1,270 acres). 80% of the transfer or RMB224,609,600.00 (approximately USD $30,895,406) will be paid in cash upon signing of the agreements. The remaining 20% will be paid in shares of common stock of the Company within three...

DENVER, July 03, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) has agreed to the final labeling for SeaStar Medical’s QUELIMMUNE™, the Selective Cytopheretic Device for pediatric patients, paving the way under the Humanitarian Use Device (HUD) designation to market the therapeutic device in the U.S. for the treatment of children weighing 10 kilograms or more with acute kidney injury (AKI) and sepsis or septic condition requiring kidney replacement therapy (KRT). “We thank the FDA for diligently working through QUELIMMUNE’s labeling. We are now...